Jeffrey D Redshaw1, Joshua A Broghammer2, Thomas G Smith3, Bryan B Voelzke4, Bradley A Erickson5, Christopher D McClung6, Sean P Elliott7, Nejd F Alsikafi8, Angela P Presson9, Michael E Aberger2, James R Craig1, William O Brant1, Jeremy B Myers1. 1. Department of Surgery, the Center for Reconstructive Urology and Men's Health, University of Utah School of Medicine, Salt Lake City, Utah. 2. Department of Urology, University of Kansas Medical Center, Kansas City, Kansas. 3. Scott Department of Urology, Baylor College of Medicine, Houston, Texas. 4. Department of Urology, Harborview Medical Center, University of Washington School of Medicine, Seattle, Washington. 5. Department of Urology, University of Iowa Carver College of Medicine, Iowa City, Iowa. 6. Department of Urology, the Ohio State Medical Center, Columbus, Ohio. 7. University of Minnesota Medical School, Minneapolis, Minnesota. 8. Department of Urology, Loyola University Chicago, Maywood, Illinois. 9. Division of Epidemiology, University of Utah, Salt Lake City, Utah.
Abstract
PURPOSE: Injection of mitomycin C may increase the success of transurethral incision of the bladder neck for the treatment of bladder neck contracture. We evaluated the efficacy of mitomycin C injection across multiple institutions. MATERIALS AND METHODS: Data on all patients who underwent transurethral incision of the bladder neck with mitomycin C from 2009 to 2014 were retrospectively reviewed from 6 centers in the TURNS. Patients with at least 3 months of cystoscopic followup were included in the analysis. RESULTS: A total of 66 patients underwent transurethral incision of the bladder neck with mitomycin C and 55 meeting the study inclusion criteria were analyzed. Mean ± SD patient age was 64 ± 7.6 years. Dilation or prior transurethral incision of the bladder neck failed in 80% (44 of 55) of patients. Overall 58% (32 of 55) of patients achieved resolution of bladder neck contracture after 1 transurethral incision of the bladder neck with mitomycin C at a median followup of 9.2 months (IQR 11.7). There were 23 patients who had recurrence at a median of 3.7 months (IQR 4.2), 15 who underwent repeat transurethral incision of the bladder neck with mitomycin C and 9 of 15 (60%) who were free of another recurrence at a median of 8.6 months (IQR 8.8), for an overall success rate of 75% (41 of 55). Incision with electrocautery (Collins knife) was predictive of success compared with cold knife incision (63% vs 50%, p=0.03). Four patients experienced serious adverse events related to mitomycin C and 3 needed or are planning cystectomy. CONCLUSIONS: The efficacy of intralesional injection of mitomycin C at transurethral incision of the bladder neck was lower than previously reported and was associated with a 7% rate of serious adverse events.
PURPOSE: Injection of mitomycin C may increase the success of transurethral incision of the bladder neck for the treatment of bladder neck contracture. We evaluated the efficacy of mitomycin C injection across multiple institutions. MATERIALS AND METHODS: Data on all patients who underwent transurethral incision of the bladder neck with mitomycin C from 2009 to 2014 were retrospectively reviewed from 6 centers in the TURNS. Patients with at least 3 months of cystoscopic followup were included in the analysis. RESULTS: A total of 66 patients underwent transurethral incision of the bladder neck with mitomycin C and 55 meeting the study inclusion criteria were analyzed. Mean ± SD patient age was 64 ± 7.6 years. Dilation or prior transurethral incision of the bladder neck failed in 80% (44 of 55) of patients. Overall 58% (32 of 55) of patients achieved resolution of bladder neck contracture after 1 transurethral incision of the bladder neck with mitomycin C at a median followup of 9.2 months (IQR 11.7). There were 23 patients who had recurrence at a median of 3.7 months (IQR 4.2), 15 who underwent repeat transurethral incision of the bladder neck with mitomycin C and 9 of 15 (60%) who were free of another recurrence at a median of 8.6 months (IQR 8.8), for an overall success rate of 75% (41 of 55). Incision with electrocautery (Collins knife) was predictive of success compared with cold knife incision (63% vs 50%, p=0.03). Four patients experienced serious adverse events related to mitomycin C and 3 needed or are planning cystectomy. CONCLUSIONS: The efficacy of intralesional injection of mitomycin C at transurethral incision of the bladder neck was lower than previously reported and was associated with a 7% rate of serious adverse events.
Authors: Rou Wang; David P Wood; Brent K Hollenbeck; Amy Y Li; Chang He; James E Montie; Jerilyn M Latini Journal: Urology Date: 2011-12-22 Impact factor: 2.649
Authors: Daniel Ramirez; Lee C Zhao; Aditya Bagrodia; J Francis Scott; Steven J Hudak; Allen F Morey Journal: Urology Date: 2013-09-18 Impact factor: 2.649
Authors: Sean P Elliott; Maxwell V Meng; Eric P Elkin; Jack W McAninch; Janeen Duchane; Peter R Carroll Journal: J Urol Date: 2007-06-13 Impact factor: 7.450
Authors: Jim C Hu; Xiangmei Gu; Stuart R Lipsitz; Michael J Barry; Anthony V D'Amico; Aaron C Weinberg; Nancy L Keating Journal: JAMA Date: 2009-10-14 Impact factor: 56.272
Authors: Rachel A Mann; Ramón Virasoro; Jessica M DeLong; Rafael E Estrella; Merycarla Pichardo; Ramón Rodríguez Lay; Gustavo Espino; Joshua D Roth; Sean P Elliott Journal: Can Urol Assoc J Date: 2021-02 Impact factor: 1.862